Takeda Welcomes You

Collaborating in an evolving environment

Takeda is delighted to be here with you at the ESID 2020 Online Meeting.

In this short video, Kasha Witkos, Head of Rare Immunology, and Kristina Allikmets, VP, Head of R&D of Plasma-Derived Therapies would like to welcome you personally to ESID 2020.

Takeda is committed more than ever to working with, and supporting, the IG community. We aim to meet evolving patient needs with a broad portfolio of IG therapies across primary immunodeficiency (PID) and secondary immunodeficiency (SID). We are also excited to announce that our fSCIG is the first and only SCIG in Europe indicated for an expanded range of SIDs, offering more patients with SIDs greater treatment choice.*1

With the global threat of the COVID-19 pandemic, Takeda has also joined other plasma leaders in the CoVIg-19 Plasma Alliance. Its aim is to encourage plasma donation to accelerate development of a hyperimmune globulin (H-Ig) known as CoVIg-19, which has the potential to become an important treatment option for the virus.

Even though the ESID 2020 Meeting is online this year, as a key sponsor, Takeda is here and aims to help address the current and future challenges faced by the IG community. So please connect with us in the Takeda Lounge.

Don’t forget to log into the ESID Meeting platform to access the Takeda Lounge.

Kasha Witkos

Kasha is the Head of Rare Immunology at Takeda. Previously, she was Global Head of the Immunology Franchise at Shire and the EMEA Region Head of Immunology at Baxalta. Kasha has over 20 years of international experience in the pharmaceutical industry, including launches in many therapy areas. She has conducted research at a number of U.S. institutions and has a degree in Molecular, Cellular and Developmental Biology/Genetics from the University of Colorado, Boulder, U.S.

Kasha Witkos
Kristina Allikmets

Kristina Allikmets, MD PhD, is the Head of R&D of the Plasma-Derived Therapies (PDT) Business Unit at Takeda. In her role, Kristina is guiding a transformational strategy for PDT R&D while leading expert teams pursuing plasma innovation to address important needs, including Takeda’s dedicated CoVIg-19 hyperimmune globulin development program. Kristina brings diverse drug development experience from multiple therapeutic areas to support Takeda’s PDT ambition. Prior to her tenure at Takeda, Kristina was Chief Medical Officer at Nycomed Pharma. Earlier in her career, she worked in academic clinical medicine, having certifications in cardiology and internal medicine. She received a medical degree and doctorate degree from the University of Tartu in Estonia.

Kristina Allikmets

*As of September 2020: Indications: Replacement therapy in adults, children and adolescents (0–18 years) in:
• Primary immunodeficiency syndrome (PID) with impaired antibody production
• Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and other proven scientific antibody failure (PSAF) or serum IgG level of <4 g/L

*PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines.
1.European Medicines Agency. Summary of Opinion. EMA/CHMP/358726/2020. Committee for Medicinal Products for Human Use (CHMP). July 2020.

This webpage and the video included in it have been initiated, produced and funded by Takeda.

Copyright 2020 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.
September 2020